Energy Metabolism and Acute Effects of Protein Diets in Metabolically Obese Normal Weight Individuals

NCT ID: NCT06802341

Last Updated: 2025-01-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-02-01

Study Completion Date

2025-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Asians tend to develop type 2 diabetes (T2D) at lower body mass index (BMI) levels and younger ages compared to other populations. This leads to a longer duration of suffering from long-term complications associated with the disease, ultimately resulting in shorter life expectancy. Notably, approximately 40% of newly diagnosed T2D cases in Asians occur in individuals considered lean, with a BMI reported to be less than 22 kg/m2. This phenomenon is termed the "Metabolically Obese Normal Weight" (MONW) phenotype. MONW individuals are characterized as having a normal body weight but exhibiting obesity-related metabolic disturbances, including excess body fat with ectopic fat deposition, insulin resistance, and dyslipidemia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Asian populations have higher prevalence of abdominal obesity, accounting for \~60% of the global diabetic population. Type 2 diabetes (T2D) developing at lower BMI levels and younger ages compared to Western populations, suggest underlying metabolic issues in Asian. A cluster of metabolically obese, normal weight (MONW) individuals are identified in 40% of newly diagnosed Asian T2D.

MONW individuals have normal body weight but exhibit obesity-related metabolic disturbances, such as excess body fat, insulin resistance, and dyslipidemia, predisposing them to develop metabolic symptoms such as T2D and cardiovascular disease. They also show reduced physical activity, lower aerobic capacity, low muscle quality and impaired thermogenesis. Elevated plasma amino acids are associated with insulin resistance, resembling obesity, diabetes and sarcopenia. Given the complex nature of MONW, further examination is needed for early diagnosis and effective prevention strategies. Increased protein intake is known to improve satiety, thermogenesis and muscle health, while enhancing insulin sensitivity and fat oxidation. High-protein diets can aid in weight loss and are often preferred over traditional calorie restriction for combating obesity. In our previous study, a 5% weight loss from calorie restriction improved body composition and metabolism in MONW individuals. Hence, this study aims to 1) better understand the physiology and energy balance of MONW individuals; 2) identify biomarkers for early diagnosis; and 3) examine the effects of high-protein diets on the metabolism of MONW individuals. The study will involve participants of Chinese descent, evaluating metabolic biomarkers in energy balance and the impact of different protein sources on their acute metabolic effects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Glucose Metabolism Disorders Obesity, Visceral Obesity; Endocrine Insulin Sensitivity Insulin Resistance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Randomized, controlled
Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Normal protein diet

Animal based protein. 60% carbohydrates, 10% proteins and 30% lipids (i.e. 0.8g of protein/kg of body weight/day)

Group Type EXPERIMENTAL

Normal protein diet

Intervention Type OTHER

Animal-based protein meal plan consisted of 60% carbohydrates, 10% proteins and 30% lipids

Animal based high protein meal

40% carbohydrates, 30% proteins and 30% lipids (i.e. 2.4g of protein/kg of body weight/day)

Group Type EXPERIMENTAL

Animal protein diet

Intervention Type OTHER

Animal based high protein meal consisting of 40% carbohydrates, 30% proteins and 30% lipids

Plant based high protein meal

40% carbohydrates, 30% proteins and 30% lipids (i.e. 2.4g of protein/kg of body weight/day)

Group Type EXPERIMENTAL

Plant based diet

Intervention Type OTHER

Plant based high protein meal consisting of 40% carbohydrates, 30% proteins and 30% lipids

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Normal protein diet

Animal-based protein meal plan consisted of 60% carbohydrates, 10% proteins and 30% lipids

Intervention Type OTHER

Animal protein diet

Animal based high protein meal consisting of 40% carbohydrates, 30% proteins and 30% lipids

Intervention Type OTHER

Plant based diet

Plant based high protein meal consisting of 40% carbohydrates, 30% proteins and 30% lipids

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Body mass index between 18.5 - 24.9 kg/m2
* Non-diabetic
* Blood pressure (≤140/90 mmHg)
* \<5% weight change in the past 6 months
* Fasting triglyceride \< 90 mg/dl and HOMA-IR ≤ 1.0 will be defined as healthy subjects
* Fasting triglyceride ≥ 90 mg/dl and HOMA-IR \> 1.0 will be defined as MONW subjects

Exclusion Criteria

* • Smoker or currently on nicotine therapy

* Regularly consume alcohol \>1 unit per day
* On hypocaloric/hypercaloric diet aiming for weight loss/gain
* An athlete or sportive person with regular exercising \>3 times per week and \>45 minutes per section.
* Currently receiving therapy (e.g. insulin) or any medication/ treatment (including supplements) that may affect glucose and lipid metabolism, energy metabolism or body composition
* Currently on steroids, protease inhibitors, or antipsychotics therapies
* Has symptomatic Irritable Bowel Syndrome
* Has glucose-6-phosphate dehydrogenase (G6PD) deficiency
* Had major medical or surgical event requiring hospitalization within the preceding 3 months
* Participated in drug trials within 3 months before the start of the study
* Donated blood within 3 months before the start of the study
* Has intolerances or allergies to any of the study foods (eg. anaphylaxis to glutens)
* Pregnant (pregnancy test will be done), lactating, or planning to be become pregnant during the study period
* Has active Tuberculosis (TB) or currently receiving treatment for TB
* Has chronic infection or is known to suffer from or has previously suffered from or is a carrier of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV)
* Has claustrophobia, trypanophobia, or hemophobia
* Unwilling to consume study foods
* Inadequate fluency in the English language
* Unable to understand the study procedures and signs forms providing written informed consent to participate in the study.
* Is a member of the research team or their immediate family members. Immediate family member is defined as a spouse, parent, child, or sibling, whether biological or legally adopted
Minimum Eligible Age

21 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Singapore Institute of Food and Biotechnology Innovation

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Melvin Leow

Prof Melvin Leow Khee-Shing

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinical Nutrition Research Centre

Singapore, Singapore, Singapore

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Singapore

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021-192

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Dietary Protein Sources and Glycemic Variability
NCT06525441 NOT_YET_RECRUITING NA